REDWOOD CITY, Calif., Nov. 3, 2016 /PRNewswire/ -- Guardant Health announced enhancements to Guardant360, the gold standard for comprehensive liquid biopsy, to help oncologists provide the best possible care for their advanced cancer patients. The new features are designed to increase the test's clinical sensitivity and utility, simplify report interpretation, and expand access to online support services for patients and doctors. They will take effect November 8, 2016. "These enhancements are a direct result of nearly 30,000 samples we have processed since we introduced Guardant360 in 2014," said Helmy Eltoukhy, Guardant Health's chief executive officer. "With every thousand samples we process, we learn something new about metastatic tumor biology, assay biochemistry, and bioinformatics. We've applied these lessons to dramatically improve the sensitivity, specificity and clinical utility of what is already the market-leading product. These improvements will let us help even more patients." Guardant360 is the first and most validated comprehensive liquid biopsy commercially available. It provides analysis of all major classes of somatic tumor alterations. The new panel interrogates 73 cancer genes from a simple blood draw, with near-perfect specificity and increased sensitivity for the detection of single nucleotide variants (SNVs), fusions and insertion and deletion alterations (indels) with low allele frequencies. "Achieving very high specificity, especially at low mutant allele frequency (MAF) is vital for liquid biopsy tests, as more than half of the alterations Guardant360 has reported were detected at an MAF below 0.4%," AmirAli Talasaz, Guardant Health's President and COO said. "The improvements we've made to our Digital Sequencing platform allow us to extend the reportable range and report SNVs and fusions down to MAFs as low as 0.04% and indels down to 0.02% in some cases." The new 73-gene Guardant360 panel includes more druggable targets and enhanced coverage of clinically important regions. It covers more sensitizing and resistance markers for targeted therapies than any other comprehensive liquid biopsy.